Evidence map›Paper›PMID 24816588›Full record

ArticlePloS one2014

Tacrolimus increases Nox4 expression in human renal fibroblasts and induces fibrosis-related genes by aberrant TGF-beta receptor signalling.

Georg Kern, Sabine M Mair, Susie-Jane Noppert, Paul Jennings, Herbert Schramek, Michael Rudnicki, Gerhard A Mueller, Gert Mayer, Christian Koppelstaetter

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Calcineurin inhibitors: a double-edged sword.American journal of physiology. Renal physiology · 2021
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Georg KernNephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Sabine M MairClinical Immunology and Infectious Diseases, Innsbruck Medical University, Innsbruck, Austria.
Susie-Jane NoppertNephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Paul JenningsPhysiology, Innsbruck Medical University, Innsbruck, Austria.
Herbert SchramekNephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Michael RudnickiNephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Gerhard A MuellerRheumatology and Nephrology, University of Goettingen, Goettingen, Germany.
Gert MayerNephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Christian KoppelstaetterNephrology and Hypertension, Innsbruck Medical University, Innsbruck, Austria.
Innsbruck Medical University · ATUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic nephrotoxicity of immunosuppressives is one of the main limiting factors in the long-term outcome of kidney transplants, leading to tissue fibrosis and ultimate organ failure. The cytokine TGF-β is considered a key factor in this process. In the human renal fibroblast cell line TK-173, the macrolide calcineurin inhibitor tacrolimus (FK-506) induced TGF-β-like effects, manifested by increased expression of NAD(P)H-oxidase 4 (Nox4), transgelin, tropomyosin 1, and procollagen α1(V) mRNA after three days. The macrolide mTOR inhibitor rapamycin had similar effects, while cyclosporine A did not induce fibrose-related genes. Concentration dependence curves were sigmoid, where mRNA expression was induced already at low nanomolar levels of tacrolimus, and reached saturation at 100-300 nM. The effects were independent of extracellular TGF-β as confirmed by the use of neutralizing antibodies, and thus most likely caused by aberrant TGF-β receptor signaling, where binding of tacrolimus to the regulatory FKBP12 protein results in a "leaky" TGF-β receptor. The myofibroblast marker α-smooth muscle actin was neither induced by tacrolimus nor by TGF-β1, indicating an incomplete activation of TK-173 fibroblasts under culture conditions. Tacrolimus- and TGF-β1-induced Nox4 protein upregulation was confirmed by Western blotting, and was accompanied by a rise in intracellular H2O2 concentration. Si-RNA mediated knock-down of Nox4 expression prevented up-regulation of procollagen α1(V) mRNA in tacrolimus-treated cells, but induced procollagen α1(V) expression in control cells. Nox4 knock-down had no significant effect on the other genes tested. TGF-β is a key molecule in fibrosis, and the constant activation of aberrant receptor signaling by tacrolimus might contribute to the long-term development of interstitial kidney fibrosis in immunosuppressed patients. Nox4 levels possibly play a regulatory role in these processes.

Indexed as

Blotting, WesternCalcineurin InhibitorsCell LineCollagen Type VFibroblastsFibrosisGene ExpressionGene Expression ProfilingHumansHydrogen PeroxideKidneyNADPH Oxidase 4NADPH OxidasesOligonucleotide Array Sequence AnalysisPhosphorylationProcollagenCalcineurin InhibitorsCollagen Type VHydrogen PeroxideNADPH Oxidase 4NADPH OxidasesNOX4 protein, humanProcollagenReceptors, Transforming Growth Factor betaSmad2 ProteinSMAD2 protein, humanTacrolimus

Identifiers

PMID24816588
PMCPMC4015940
OpenAlexW1997678469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.